Rispolept Consta - 10 years of practice in Russia: some conclusions

Federal Medical Research Centre of Psychiatry and Narcology

Summary: Summary The article presents a literature review of the new world research on risperidone long-acting injectable (RLAI) (Rispolept CONSTA) and summarizes a10-year experience of its use in Russia. RLAI was the first long-acting antipsychotic with the unique technology of biopolymeric microspheres, which combined advantages of long-term action with the efficacy and safety of the second-generation antipsychotics. The guaranteed and controlled release drug delivery provide better adherence and achievement of more stable and deep remissions, which are associated with less exacerbations, drop in hospitalization rate, higher levels of functioning and quality of life and with better outcomes in general.

КОНТАКТ: k_oleneva@mail.ru